EUCTR2016-001121-14-CZ进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Clinical diagnosis of granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis, consistent with Chapel-Hill Consensus Conference definitions
- •2. Aged at least 18 years, with newly-diagnosed or relapsed AAV where treatment with cyclophosphamide or rituximab is needed; where approved, adolescents (12-17 year old) may be enrolled
- •3. Positive test for anti-PR3 or anti-MPO (current or historic) antibodies
- •4. At least one major item, or at least 3 minor items, or at least the 2 renal items of proteinuria and hematuria in the BVAS
- •5. Estimated glomerular filtration rate =15 mL/minute/1.73 m2 (using the MDRD method for adults, and modified Schwartz equation for adolescents ) at screening
- •6. Willing and able to give written Informed Consent and to comply with the requirements of the study protocol; written Informed Consent should be obtained from the legal guardian in accordance with regional laws or regulations for patients 12 to 17 years of age
- •7. Judged by the Investigator to be fit for the study, based on medical history, physical examination (including electrocardiogram [ECG]), and clinical laboratory assessments.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 10
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 240
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1. Pregnant or breast-feeding
- •2. Alveolar hemorrhage requiring invasive pulmonary ventilation support anticipated to last beyond the screening period of the study
- •3. Any other known multi-system autoimmune disease including eosinophilic granulomatosis with polyangiitis (Churg-Strauss), systemic lupus erythematosus, IgA vasculitis (Henoch-Schönlein), rheumatoid vasculitis, Sjögren's syndrome, anti-glomerular basement membrane disease, or cryoglobulinemic vasculitis
- •4. Required dialysis or plasma exchange within 12 weeks prior to screening
- •5. Have had a kidney transplant
- •6. Received cyclophosphamide within 12 weeks prior to screening; if on azathioprine, mycophenolate mofetil, or methotrexate at the time of screening, these drugs must be withdrawn prior to receiving the cyclophosphamide or rituximab dose on Day 1
- •7. Received intravenous glucocorticoids, >3000 mg methylprednisolone equivalent, within 4 weeks prior to screening
- •8. Have been taking an oral daily dose of a glucocorticoid of more than 10 mg prednisone-equivalent for more than 6 weeks continuously prior to the screening visit
- •9. Received rituximab or other B-cell antibody within 52 weeks of screening or 26 weeks provided B cell reconstitution has occurred (i.e., CD19 count > 0.01x109/L); received anti-TNF treatment, abatacept, alemtuzumab, IVIg, belimumab, tocilizumab, or eculizumab within 12 weeks prior to screening
- •10. Currently taking a strong inducer of the cytochrome P450 3A4 (CYP3A4) enzyme, such as carbamazepine, phenobarbital, phenytoin, rifampin, or St. John’s wort
- •11. Any of the following within 12 weeks prior to screening: symptomatic congestive heart failure requiring prescription medication, unstable angina (unless successfully treated with stent or bypass surgery), clinically significant cardiac arrhythmia, myocardial infarction or stroke
- •12. History or presence of any form of cancer within the 5 years prior to screening, with the exception of excised basal cell or squamous cell carcinoma of the skin, or carcinoma in situ such as cervical or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis
- •13. Evidence of tuberculosis based on interferon ? release assay (IGRA), tuberculin purified protein derivative (PPD) skin test, or chest radiography (X rays or CT scan) done at screening or within 6 weeks prior to screening
- •14. HBV, HCV, or HIV viral screening test showing evidence of active or chronic prior viral infection done at screening or within 6 weeks prior to screening
- •15. Received a live vaccine within 4 weeks prior to screening
- •16. WBC count less than 3500/µL, or neutrophil count less than 1500/µL, or lymphocyte count less than 500/µL before start of dosing
- •17. Evidence of hepatic disease: AST, ALT, alkaline phosphatase, or bilirubin > 3 times the upper limit of normal before start of dosing
- •18. Clinically significant abnormal ECG during screening, e.g., QTcF greater than 450 msec
- •19. Known hypersensitivity to CCX168 or inactive ingredients of the CCX168 capsules (including gelatin, polyethylene glycol, or Cremophor), cyclophosphamide or its metabolites (for patients sched
研究者
相似试验
进行中（未招募）
1 期
A study to assess the benefit of treatment beyond progression with enzalutamide in men who are starting treatment with docetaxel after worsening of their prostate cancer when taking enzalutamide aloneMetastatic Castrate Resistant Prostate CancerMedDRA version: 20.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004711-50-BEAstellas Pharma Europe Ltd650
进行中（未招募）
不适用
A Study of LY2835219 Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerMedDRA version: 17.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancerEUCTR2013-004728-13-FREli Lilly and Company550
进行中（未招募）
不适用
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168, a new drug for the treatment of Vasculitis of a certain type, called ANCA-Associated Vasculitis (AAV).on-life-threatening anti-neutrophil cytoplasmic antibody vasculitis (AAV) with mild-to-moderate renal involvementMedDRA version: 17.0Level: PTClassification code 10047115Term: VasculitisSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-001222-15-SEChemoCentryx, Inc.60
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy Effects of ART-123 on Subjects with Sepsis and Disseminated Intravascular CoagulatioSepsis and disseminated intravascular coagulation.MedDRA version: 9.1 Level: LLT Classification code 10040047 Term: SepsisMedDRA version: 9.1 Level: LLT Classification code 10013442 Term: Disseminated intravascular coagulationEUCTR2007-002035-81-GBArtisan Pharma, Inc.800
进行中（未招募）
1 期
A Study of abemaciclib Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast CancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancerEUCTR2013-004728-13-DEEli Lilly and Company710